BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1696 related articles for article (PubMed ID: 25556173)

  • 1. Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.
    Loupy A; Vernerey D; Tinel C; Aubert O; Duong van Huyen JP; Rabant M; Verine J; Nochy D; Empana JP; Martinez F; Glotz D; Jouven X; Legendre C; Lefaucheur C
    J Am Soc Nephrol; 2015 Jul; 26(7):1721-31. PubMed ID: 25556173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients.
    Halloran PF; Chang J; Famulski K; Hidalgo LG; Salazar ID; Merino Lopez M; Matas A; Picton M; de Freitas D; Bromberg J; Serón D; Sellarés J; Einecke G; Reeve J
    J Am Soc Nephrol; 2015 Jul; 26(7):1711-20. PubMed ID: 25377077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term kidney allograft survival in patients with transplant glomerulitis.
    Nabokow A; Dobronravov VA; Khrabrova M; Gröne HJ; Gröne E; Hallensleben M; Kieneke D; Weithofer P; Smirnov AV; Kliem V
    Transplantation; 2015 Feb; 99(2):331-9. PubMed ID: 25594551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection.
    Kikić Ž; Kainz A; Kozakowski N; Oberbauer R; Regele H; Bond G; Böhmig GA
    Clin J Am Soc Nephrol; 2015 Aug; 10(8):1435-43. PubMed ID: 26071493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.
    Wiebe C; Gibson IW; Blydt-Hansen TD; Pochinco D; Birk PE; Ho J; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2015 Nov; 15(11):2921-30. PubMed ID: 26096305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.
    Cherukuri A; Mehta R; Sharma A; Sood P; Zeevi A; Tevar AD; Rothstein DM; Hariharan S
    Kidney Int; 2019 Jul; 96(1):202-213. PubMed ID: 31029504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between a change in donor kidney function and long-term allograft outcomes in kidney transplant recipients.
    Oh IH; Lee CH; Kim GH; Kang CM; Park JS
    Artif Organs; 2015 Mar; 39(3):254-9. PubMed ID: 25205383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
    Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
    Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
    Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
    Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection.
    Matignon M; Muthukumar T; Seshan SV; Suthanthiran M; Hartono C
    Transplantation; 2012 Sep; 94(6):603-11. PubMed ID: 22932115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Early Complement Activation in Renal Transplantation Associated with Later Graft Outcome?
    Bobka S; Ebert N; Koertvely E; Jacobi J; Wiesener M; Büttner-Herold M; Amann K; Daniel C
    Kidney Blood Press Res; 2018; 43(5):1488-1504. PubMed ID: 30286468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression patterns of B cells in acute kidney transplant rejection.
    Carpio VN; Noronha Ide L; Martins HL; Jobim LF; Gil BC; Külzer AS; Loreto Mda S; Gonçalves LF; Manfro RC; Veronese FV
    Exp Clin Transplant; 2014 Oct; 12(5):405-14. PubMed ID: 25299368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Mediated Rejection Due to Preexisting versus
    Aubert O; Loupy A; Hidalgo L; Duong van Huyen JP; Higgins S; Viglietti D; Jouven X; Glotz D; Legendre C; Lefaucheur C; Halloran PF
    J Am Soc Nephrol; 2017 Jun; 28(6):1912-1923. PubMed ID: 28255002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microvascular inflammation in early protocol biopsies of renal allografts in cases of chronic active antibody-mediated rejection.
    Tsuji T; Yanai M; Itami H; Ishii Y; Akimoto M; Fukuzawa N; Harada H; Fukasawa Y
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():26-30. PubMed ID: 26031582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.
    Viglietti D; Loupy A; Aubert O; Bestard O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Jouven X; Delahousse M; Kamar N; Lefaucheur C
    J Am Soc Nephrol; 2018 Feb; 29(2):606-619. PubMed ID: 29255058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
    Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute cellular rejection: impact of donor-specific antibodies and C4d.
    Willicombe M; Roufosse C; Brookes P; McLean AG; Galliford J; Cairns T; Cook TH; Taube D
    Transplantation; 2014 Feb; 97(4):433-9. PubMed ID: 24430742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
    Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
    Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic Long-term Outcomes of Living-Related Kidney Transplantations Depending on the Donor-Recipient Relationship.
    Khadzhynov D; Halleck F; Lehner L; Schmidt D; Schrezenmeier E; Budde K; Staeck O
    Transplant Proc; 2017 Dec; 49(10):2265-2268. PubMed ID: 29198658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mid-Term Outcomes After Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?
    Okada M; Tomosugi T; Futamura K; Hiramitsu T; Goto N; Narumi S; Takeda A; Watarai Y
    Transplant Proc; 2020 Dec; 52(10):3051-3057. PubMed ID: 32694058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.